BeOne Medicines Ltd. cotiza a 349.08 USD y tiene una capitalización bursátil de $39.7B. En los últimos 12 meses ha facturado $6.1B con un margen de flujo de caja libre del 17.6%. Cotiza a 29.9 veces su flujo de caja libre (P/FCF) y a un PER de 60.6. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of vari…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.05 | $1.96 | $0.58 |
| Estimado | $1.88 | $1.63 | $0.81 | $1.30 |
| Sorpresa | — | +25.8% | +142.0% | -55.4% |
| Métrica | ONC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 87.5% | 57.0% | +30.4% |
| Operating Margin | 8.4% | -38.6% | +47.0% |
| Net Margin | 5.4% | -33.6% | +38.9% |
| FCF Margin | 17.6% | -13.9% | +31.5% |
| ROE | 6.6% | -40.4% | +47.0% |
| ROA | 3.5% | -32.0% | +35.5% |
| Current Ratio | 3.41 | 2.84 | +0.57 |
| Debt / Equity | 0.19 | 0.28 | -0.09 |